{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Han W"],"pubmed_abstract":["<h4>Background</h4>The surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal squamous cell carcinoma (ESCC) remains unelucidated. This study aimed to determine the validity of PFS as a surrogate endpoint for OS in ESCC patients treated with definitive radiotherapy or definitive chemoradiotherapy (dRT/dCRT), as well as characterize the prognostic factors and survival of such patients.<h4>Methods</h4>A total of 3662 patients from 10 cancer centers were enrolled. One-, 2-, and 3-year PFS (PFS12, PFS24, and PSF36, respectively) were used as time points for analysis. At each time point, ESCC-specific mortality and OS were characterized using competing risk and conditional survival models, while correlation between PFS and OS was evaluated by linear regression.<h4>"],"journal":["Therapeutic advances in medical oncology"],"pagination":["17588359221131526"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9619262"],"repository":["biostudies-literature"],"pubmed_title":["Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis."],"pmcid":["PMC9619262"],"pubmed_authors":["Zhang K","Liu M","Han W","Deng L","Bi N","Zhao Y","Wang L","Liang J","Wang W","Wang X","Wang Y","Deng W","Li G","Li C","Chen J","Xiao Z","Sun X","Li L","Chang X","Zhou Z","Chen D","Zhang W","Lv J","Qiao X","Zhang T","Pang Q","Ni W","Han C","Feng Q","Zhu S"],"additional_accession":[]},"is_claimable":false,"name":"Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis.","description":"<h4>Background</h4>The surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal squamous cell carcinoma (ESCC) remains unelucidated. This study aimed to determine the validity of PFS as a surrogate endpoint for OS in ESCC patients treated with definitive radiotherapy or definitive chemoradiotherapy (dRT/dCRT), as well as characterize the prognostic factors and survival of such patients.<h4>Methods</h4>A total of 3662 patients from 10 cancer centers were enrolled. One-, 2-, and 3-year PFS (PFS12, PFS24, and PSF36, respectively) were used as time points for analysis. At each time point, ESCC-specific mortality and OS were characterized using competing risk and conditional survival models, while correlation between PFS and OS was evaluated by linear regression.<h4>","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-05T13:27:36.307Z","creation":"2025-04-05T13:27:36.307Z"},"accession":"S-EPMC9619262","cross_references":{"pubmed":["36324733"],"doi":["10.1177/17588359221131526"]}}